# Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis

> **NCT01146561** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 2 (actual)

## Conditions studied

- Chronic Pancreatitis

## Interventions

- **BIOLOGICAL:** Tanezumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01146561
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10-13
- **Primary completion:** 2011-03-22
- **Final completion:** 2011-03-22
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2021-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01146561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01146561, "Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01146561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*